CoChat
Sign Up
Cited by 205

Coming of age: the artificial pancreas for type 1 diabetes

Thabit, Hood, Hovorka, Roman·2016·Diabetologia
DOI 10.1007/s00125-016-4022-4PMC PMC4969330
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-016-4022-4

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Advanced device technology, including continuous glucose monitors (CGMs) and continuous subcutaneous insulin infusion (CSII) pumps, improves care for patients living with type 1 diabetes and has recently moved to closed-loop artificial pancreas (AP) systems.

    “Advanced device technology, including continuous glucose monitors (CGMs) and continuous subcutaneous insulin infusion (CSII) pumps, improves care for patients living with type 1 diabetes and has recently moved to closed-loop artificial pancreas (AP) systems.”

    From Real-Time Detection of Infusion Site Failures in a Closed-Loop Artificial Pancreas (2018) · cites this paper as [3]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 89

  1. [2]Pickup JC Keen H Parsons JA Alberti KG Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia Br Med J 1978 1 204 207 10.1136/bmj.1.6107.204 340000 PMC1602534 · DOI
  2. [3]Tamborlane WV Sherwin RS Genel M Felig P Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump N Engl J Med 1979 300 573 578 10.1056/NEJM197903153001101 763270 · DOI
  3. [4]Pickup JC Management of diabetes mellitus: is the pump mightier than the pen? Nat Rev Endocrinol 2012 8 425 433 10.1038/nrendo.2012.28 22371161 · DOI
  4. [5]Tamada JA Garg S Jovanovic L Pitzer KR Fermi S Potts RO Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team JAMA 1999 282 1839 1844 10.1001/jama.282.19.1839 10573275 · DOI
  5. [6]Garg SK Potts RO Ackerman NR Fermi SJ Tamada JA Chase HP Correlation of fingerstick blood glucose measurements with GlucoWatch biographer glucose results in young subjects with type 1 diabetes Diabetes Care 1999 22 1708 1714 10.2337/diacare.22.10.1708 10526740 · DOI
  6. [7]Rodbard D Continuous glucose monitoring: a review of successes, challenges, and opportunities Diabetes Technol Ther 2016 18 Suppl 2 S23 S213 10.1089/dia.2015.0417 26784127 PMC4717493 · DOI
  7. [8]Thabit H Tauschmann M Allen JM Home use of an artificial beta cell in type 1 diabetes N Engl J Med 2015 373 2129 2140 10.1056/NEJMoa1509351 26379095 PMC4697362 · DOI · Paper page
  8. [9]Peyser T Dassau E Breton M Skyler JS The artificial pancreas: current status and future prospects in the management of diabetes Ann N Y Acad Sci 2014 1311 102 123 10.1111/nyas.12431 24725149 · DOI · Paper page
  9. [10]Hovorka R Closed-loop insulin delivery: from bench to clinical practice Nat Rev Endocrinol 2011 7 385 395 10.1038/nrendo.2011.32 21343892 · DOI · Paper page
  10. [11]Ly TT Nicholas JA Retterath A Lim EM Davis EA Jones TW Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial JAMA 2013 310 1240 1247 10.1001/jama.2013.277818 24065010 · DOI · Paper page
  11. [12]Bergenstal RM Klonoff DC Garg SK Threshold-based insulin-pump interruption for reduction of hypoglycemia N Engl J Med 2013 369 224 232 10.1056/NEJMoa1303576 23789889 · DOI · Paper page
  12. [13]Maahs DM Calhoun P Buckingham BA A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes Diabetes Care 2014 37 1885 1891 10.2337/dc13-2159 24804697 PMC4067393 · DOI
  13. [14]Kropff J DeVries JH Continuous glucose monitoring, future products, and update on worldwide artificial pancreas projects Diabetes Technol Ther 2016 18 Suppl 2 S2-53 S2-63 10.1089/dia.2015.0345 26784131 PMC4717501 · DOI
  14. [15]Thabit H Hovorka R Bringing closed- loop home: recent advances in closed- loop insulin delivery Curr Opin Endocrinol Diabetes Obes 2014 21 95 101 10.1097/MED.0000000000000048 24569550 · DOI
  15. [16]The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993 329 977 986 10.1056/NEJM199309303291401 8366922 · DOI · Paper page
  16. [17]Nathan DM Cleary PA Backlund JY Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 2005 353 2643 2653 10.1056/NEJMoa052187 16371630 PMC2637991 · DOI · Paper page
  17. [18]Cryer PE The barrier of hypoglycemia in diabetes Diabetes 2008 57 3169 3176 10.2337/db08-1084 19033403 PMC2584119 · DOI · Paper page
  18. [19]Pickup JC Sutton AJ Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion Diabet Med 2008 25 765 774 10.1111/j.1464-5491.2008.02486.x 18644063 · DOI
  19. [20]Pedersen-Bjergaard U Kristensen PL Beck-Nielsen H Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial Lancet Diabetes Endocrinol 2014 2 553 561 10.1016/S2213-8587(14)70073-7 24794703 · DOI
  20. [21]Ruan Y Thabit H Leelarathna L Variability of insulin requirements over 12 weeks of closed-loop insulin delivery in adults with type 1 diabetes Diabetes Care 2016 39 830 832 10.2337/dc15-2623 26965717 · DOI
  21. [23]Manohar C Levine JA Nandy DK The effect of walking on postprandial glycemic excursion in patients with type 1 diabetes and healthy people Diabetes Care 2012 35 2493 2499 10.2337/dc11-2381 22875231 PMC3507567 · DOI · Paper page
  22. [24]Bally L Zueger T Buehler T Metabolic and hormonal response to intermittent high-intensity and continuous moderate intensity exercise in individuals with type 1 diabetes: a randomised crossover study Diabetologia 2016 59 776 784 10.1007/s00125-015-3854-7 26739816 · DOI
  23. [26]Wong JC Neinstein AB Spindler M Adi S A minority of patients with type 1 diabetes routinely downloads and retrospectively reviews device data Diabetes Technol Ther 2015 17 555 562 10.1089/dia.2014.0413 26133226 PMC4529086 · DOI
  24. [27]Beck RW Downloading diabetes device data: empowering patients to download at home to achieve better outcomes Diabetes Technol Ther 2015 17 536 537 10.1089/dia.2015.0169 26060890 · DOI
  25. [28]Simmons JH Chen V Miller KM Differences in the management of type 1 diabetes among adults under excellent control compared with those under poor control in the T1D Exchange Clinic Registry Diabetes Care 2013 36 3573 3577 10.2337/dc12-2643 24026543 PMC3816911 · DOI
  26. [29]Hovorka R Artificial pancreas project at Cambridge 2013 Diabet Med 2015 32 987 992 10.1111/dme.12766 25819473 PMC4504774 · DOI
  27. [30]Johnson SR Cooper MN Davis EA Jones TW Hypoglycaemia, fear of hypoglycaemia and quality of life in children with Type 1 diabetes and their parents Diabet Med 2013 30 1126 1131 10.1111/dme.12247 23808967 · DOI
  28. [31]Brod M Wolden M Christensen T Bushnell DM A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function Diabetes Obes Metab 2013 15 546 557 10.1111/dom.12070 23350726 PMC3662999 · DOI
  29. [32]van Bon AC Brouwer TB von Basum G Hoekstra JB DeVries JH Future acceptance of an artificial pancreas in adults with type 1 diabetes Diabetes Technol Ther 2011 13 731 736 10.1089/dia.2011.0013 21504332 · DOI
  30. [33]Elleri D Acerini CL Allen JM Parental attitudes towards overnight closed-loop glucose control in children with type 1 diabetes Diabetes Technol Ther 2010 12 35 39 10.1089/dia.2009.0084 20082583 · DOI
  31. [34]Barnard KD Pinsker JE Oliver N Astle A Dassau E Kerr D Future artificial pancreas technology for type 1 diabetes: what do users want? Diabetes Technol Ther 2015 17 311 315 10.1089/dia.2014.0316 25629627 · DOI
  32. [35]Wong JC Foster NC Maahs DM Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry Diabetes Care 2014 37 2702 2709 10.2337/dc14-0303 25011947 PMC4392936 · DOI · Paper page
  33. [36]de Bock M Cooper M Retterath A Continuous glucose monitoring adherence: Lessons from a clinical trial to predict outpatient behavior J Diabetes Sci Technol 2016 10 627 632 10.1177/1932296816633484 26908570 PMC5038543 · DOI
  34. [37]Barnard KD Wysocki T Thabit H Psychosocial aspects of closed- and open-loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting Diabet Med 2015 32 601 608 10.1111/dme.12706 25615888 · DOI
  35. [38]Ziegler C Liberman A Nimri R Reduced worries of hypoglycaemia, high satisfaction, and increased perceived ease of use after experiencing four nights of MD-Logic artificial pancreas at home (DREAM4) J Diabetes Res 2015 2015 590308 10.1155/2015/590308 26581230 PMC4637058 · DOI
  36. [39]Bruni A Gala-Lopez B Pepper AR Abualhassan NS Shapiro AJ Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges Diabetes Metab Syndr Obes 2014 7 211 223 25018643 PMC4075233
  37. [40]Kelly WD Lillehei RC Merkel FK Idezuki Y Goetz FC Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy Surgery 1967 61 827 837 5338113
  38. [42]Gruessner AC, Gruessner RW (2012) Pancreas transplant outcomes for United States and non United States cases as reported to the United Network for Organ Sharing and the International Pancreas Transplant Registry as of December 2011. Clin Transpl:23-40 23721008
  39. [43]de Ferranti SD de Boer IH Fonseca V Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association Diabetes Care 2014 37 2843 2863 10.2337/dc14-1720 25114297 PMC4170130 · DOI
  40. [44]Rudolph EN Finger EB Chandolias N Kandaswamy R Sutherland DE Dunn TB Outcomes of pancreas retransplantation Transplantation 2015 99 367 374 10.1097/TP.0000000000000566 25594555 · DOI
  41. [45]Lakey JR Burridge PW Shapiro AM Technical aspects of islet preparation and transplantation Transpl Int 2003 16 613 632 10.1111/j.1432-2277.2003.tb00361.x 12928769 · DOI
  42. [46]Ryan EA Paty BW Senior PA Five-year follow-up after clinical islet transplantation Diabetes 2005 54 2060 2069 10.2337/diabetes.54.7.2060 15983207 · DOI · Paper page
  43. [47]Shapiro AM State of the art of clinical islet transplantation and novel protocols of immunosuppression Curr Diab Rep 2011 11 345 354 10.1007/s11892-011-0217-8 21830042 · DOI
  44. [48]Phillip M Battelino T Atlas E Nocturnal glucose control with an artificial pancreas at a diabetes camp N Engl J Med 2013 368 824 833 10.1056/NEJMoa1206881 23445093 · DOI
  45. [49]Russell SJ El-Khatib FH Sinha M Outpatient glycemic control with a bionic pancreas in type 1 diabetes N Engl J Med 2014 371 313 325 10.1056/NEJMoa1314474 24931572 PMC4183762 · DOI
  46. [50]Leelarathna L Nodale M Allen JM Evaluating the accuracy and large inaccuracy of two continuous glucose monitoring systems Diabetes Technol Ther 2013 15 143 149 10.1089/dia.2012.0245 23256605 PMC3558677 · DOI
  47. [51]Thabit H Leelarathna L Wilinska ME Accuracy of continuous glucose monitoring during three closed-loop home studies under free-living conditions Diabetes Technol Ther 2015 17 801 807 10.1089/dia.2015.0062 26241693 PMC4649721 · DOI
  48. [54]Steil GM Rebrin K Darwin C Hariri F Saad MF Feasibility of automating insulin delivery for the treatment of type 1 diabetes Diabetes 2006 55 3344 3350 10.2337/db06-0419 17130478 · DOI
  49. [55]Hovorka R Canonico V Chassin LJ Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes Physiol Meas 2004 25 905 920 10.1088/0967-3334/25/4/010 15382830 · DOI · Paper page
  50. [56]Weinzimer SA Steil GM Swan KL Dziura J Kurtz N Tamborlane WV Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas Diabetes Care 2008 31 934 939 10.2337/dc07-1967 18252903 · DOI
  51. [57]El-Khatib FH Russell SJ Nathan DM Sutherlin RG Damiano ER A bihormonal closed-loop artificial pancreas for type 1 diabetes Sci Transl Med 2010 2 27ra27 10.1126/scitranslmed.3000619 20393188 PMC4242106 · DOI · Paper page
  52. [58]Haidar A Elleri D Kumareswaran K Pharmacokinetics of insulin aspart in pump-treated subjects with type 1 diabetes: reproducibility and effect of age, weight, and duration of diabetes Diabetes Care 2013 36 e173 e174 10.2337/dc13-0485 24065849 PMC3781562 · DOI
  53. [60]Garg SK Voelmle M Gottlieb PA Time lag characterization of two continuous glucose monitoring systems Diabetes Res Clin Pract 2010 87 348 353 10.1016/j.diabres.2009.11.014 20022127 · DOI
  54. [61]Basu A Dube S Veettil S Time lag of glucose from intravascular to interstitial compartment in type 1 diabetes J Diabetes Sci Technol 2015 9 63 68 10.1177/1932296814554797 25305282 PMC4495531 · DOI
  55. [62]Heise T Hövelmann U Brøndsted L Adrian CL Nosek L Haahr H Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart Diabetes Obes Metab 2015 17 682 688 10.1111/dom.12468 25846340 PMC5054830 · DOI
  56. [63]Setji TL, Hong BD, Feinglos MN (2015) Technosphere insulin: inhaled prandial insulin. Expert Opin Biol Ther:1-7 26567896
  57. [64]Zisser H Dassau E Lee JJ Harvey RA Bevier W Doyle FJ Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion J Diabetes Sci Technol 2015 9 564 572 10.1177/1932296815582061 25901023 PMC4604530 · DOI
  58. [65]El-Laboudi AH Oliver N Towards a physiological prandial insulin profile: Enhancement of subcutaneously injected prandial insulin using local warming devices Diabetes Ther 2015 6 257 272 10.1007/s13300-015-0125-z 26328536 PMC4575301 · DOI
  59. [66]Wang X Ioacara S DeHennis A Long-term home study on nocturnal hypoglycemic alarms using a new fully implantable continuous glucose monitoring system in type 1 diabetes Diabetes Technol Ther 2015 17 780 786 10.1089/dia.2014.0375 26177299 · DOI
  60. [67]Bailey T Bode BW Christiansen MP Klaff LJ Alva S The performance and usability of a factory-calibrated flash glucose monitoring system Diabetes Technol Ther 2015 17 787 794 10.1089/dia.2014.0378 26171659 PMC4649725 · DOI · Paper page
  61. [68]Hajnsek M Nacht B Sax S List EJ Klimant I Sinner F The single-port concept: combining optical glucose measurement with insulin infusion Acta Diabetol 2014 51 883 886 10.1007/s00592-014-0578-y 24687695 · DOI
  62. [69]Del Favero S Place J Kropff J Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes Diabetes Obes Metab 2015 17 468 476 10.1111/dom.12440 25600304 · DOI
  63. [70]Del Favero S Bruttomesso D Di Palma F First use of model predictive control in outpatient wearable artificial pancreas Diabetes Care 2014 37 1212 1215 10.2337/dc13-1631 24757228 · DOI · Paper page
  64. [71]Grosman B Ilany J Roy A Hybrid closed-loop insulin delivery in type 1 diabetes during supervised outpatient conditions J Diabetes Sci Technol 2016 10 708 731 10.1177/1932296816631568 26880389 PMC5038540 · DOI
  65. [72]Ly TT Breton MD Keith-Hynes P Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp Diabetes Care 2014 37 2310 2316 10.2337/dc14-0147 24879841 PMC4179507 · DOI
  66. [73]Ly TT Roy A Grosman B Day and night closed-loop control using the integrated Medtronic hybrid closed-loop system in type 1 diabetes at diabetes camp Diabetes Care 2015 38 1205 1211 10.2337/dc14-3073 26049550 · DOI
  67. [74]Kovatchev BP Renard E Cobelli C Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas Diabetes Care 2014 37 1789 1796 10.2337/dc13-2076 24929429 PMC4067397 · DOI
  68. [75]Brown SA Kovatchev BP Breton MD Multinight “bedside” closed-loop control for patients with type 1 diabetes Diabetes Technol Ther 2015 17 203 209 10.1089/dia.2014.0259 25594434 PMC4346235 · DOI
  69. [76]Nimri R Muller I Atlas E MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial Diabetes Care 2014 37 3025 3032 10.2337/dc14-0835 25078901 · DOI
  70. [77]Leelarathna L Dellweg S Mader JK Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study Diabetes Care 2014 37 1931 1937 10.2337/dc13-2911 24963110 · DOI
  71. [78]Tauschmann M Allen JM Wilinska ME Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial Diabetes Care 2016 26740634 PMC4915556
  72. [79]Kropff J Del Favero S Place J 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial Lancet Diabetes Endocrinol 2015 3 939 947 10.1016/S2213-8587(15)00335-6 26432775 · DOI
  73. [80]Barnard KD, Wysocki T, Allen JM et al (2014) Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents. BMJ Open Diabetes Res Care 2:e000025. doi:10.1136/bmjdrc-2014-000025 PMC4212573 25452866 · DOI · Paper page
  74. [81]Bakhtiani PA Zhao LM El Youssef J Castle JR Ward WK A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy Diabetes Obes Metab 2013 15 1065 1070 10.1111/dom.12107 23602044 PMC3766424 · DOI
  75. [82]Haidar A Smaoui MR Legault L Rabasa-Lhoret R The role of glucagon in the artificial pancreas Lancet Diabetes Endocrinol 2016 4 476 479 10.1016/S2213-8587(16)30006-7 27138734 · DOI
  76. [83]Russell SJ Hillard MA Balliro C Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial Lancet Diabetes Endocrinol 2016 4 233 243 10.1016/S2213-8587(15)00489-1 26850709 PMC4799495 · DOI
  77. [84]Haidar A Legault L Matteau-Pelletier L Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial Lancet Diabetes Endocrinol 2015 3 595 604 10.1016/S2213-8587(15)00141-2 26066705 · DOI
  78. [85]van Bon AC Luijf YM Koebrugge R Koops R Hoekstra JB Devries JH Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours Diabetes Technol Ther 2014 16 131 136 10.1089/dia.2013.0166 24224750 PMC3934514 · DOI
  79. [86]Steiner SS Li M Hauser R Pohl R Stabilized glucagon formulation for bihormonal pump use J Diabetes Sci Technol 2010 4 1332 1337 10.1177/193229681000400606 21129327 PMC3005042 · DOI
  80. [87]Jackson MA Caputo N Castle JR David LL Roberts CT Ward WK Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas Curr Diab Rep 2012 12 705 710 10.1007/s11892-012-0320-5 22972416 PMC3970213 · DOI
  81. [89]Weinzimer SA Sherr JL Cengiz E Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes Diabetes Care 2012 35 1994 1999 10.2337/dc12-0330 22815298 PMC3447854 · DOI
  82. [90]Renukuntla VS Ramchandani N Trast J Cantwell M Heptulla RA Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm J Diabetes Sci Technol 2014 8 1011 1017 10.1177/1932296814542153 25030181 PMC4455387 · DOI
  83. [91]Kowalski A Pathway to artificial pancreas systems revisited: moving downstream Diabetes Care 2015 38 1036 1043 10.2337/dc15-0364 25998296 · DOI
  84. [92]Trevitt S Simpson S Wood A Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development? J Diabetes Sci Technol 2015 10 714 723 10.1177/1932296815617968 26589628 PMC5038530 · DOI
  85. [93]O’Keeffe DT Maraka S Basu A Keith-Hynes P Kudva YC Cybersecurity in artificial pancreas experiments Diabetes Technol Ther 2015 17 664 666 10.1089/dia.2014.0328 25923544 PMC4556085 · DOI
  86. [94]Dauber A Corcia L Safer J Agus MS Einis S Steil GM Closed-loop insulin therapy improves glycemic control in children aged <7 years: a randomized controlled trial Diabetes Care 2013 36 222 227 10.2337/dc12-1079 23033237 PMC3554296 · DOI
  87. [95]Murphy HR Elleri D Allen JM Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes Diabetes Care 2011 34 406 411 10.2337/dc10-1796 21216859 PMC3024358 · DOI
  88. [96]Leelarathna L English SW Thabit H Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial Crit Care 2013 17 R159 10.1186/cc12838 23883613 PMC4056260 · DOI
  89. [97]Thabit H Hovorka R Glucose control in non-critically ill inpatients with diabetes: towards closed-loop Diabetes Obes Metab 2014 16 500 509 10.1111/dom.12228 24267153 · DOI

Cited by

Sorted by citations

Authors
Thabit, H., & Hovorka, R.
Venue
Diabetologia
Publisher
Springer Science and Business Media LLC
Published
2016-06-30
Volume
59
Issue
9
Pages
1795-1805
ISSN
  • 0012-186X
  • 1432-0428
DOI
10.1007/s00125-016-4022-4
PMC
PMC4969330
Cited by
205
References
8
Language
en
Licence
creativecommons.org/licenses/by/4.0 (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review